In mCRPC patients previously treated with docetaxel and either abiraterone or enzalutamide, third-line therapy with cabazitaxel offered longer imaging-based progression-free survival and overall survival compared with switching patients to the other antiandrogen, the CARD study found.
In a population-based study, PN was associated with improved cancer-specific survival by 56%.
In a cohort study, 7% of patients had life-threatening complications associated with urethral stricture.
Efficacy benefits of pembrolizumab plus axitinib over sunitinib were also observed in patients with disease characterized by sarcomatoid features.
Longer follow-up of patients in the KEYNOTE-052 trial confirms the anti-tumor effect of first-line pembrolizumab in patients with cisplatin-ineligible advanced urothelial carcinoma.
The median duration of complete response to atezolizumab in patients with locally advanced or metastatic urothelial carcinoma is more than 2 years, new data suggest.
In a phase 2 study, patients with metastatic urothelial carcinoma who had stable disease on first-line platinum-based chemotherapy experienced a delay in disease progression when switched to pembolizumab.
Addition of enzalutamide vs another nonsteroidal anti-androgen to standard of care is associated with significant improvement in overall survival among men with metastatic hormone-sensitive prostate cancer.
In a head-to-head comparative study involving PCa patients with early biochemical recurrence following radical surgery, PSMA PET/CT had significantly higher cancer detection rates than fluciclovine PET/CT.
Nodal and metastatic prostate cancer at diagnosis increased after 2008, when the USPSTF recommended against PSA screening for men aged 75 or older, and again when it expanded the recommendation for all men.
